Back to top

Celldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright

Celldex (CLDX), at EADV 2025, disclosed new data from its Phase 2 study assessing barzolvolimab in CSU, showing that barzo has rapid efficacy in Ch...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Celldex Therapeutics, Inc. (CLDX)